



FOR IMMEDIATE RELEASE

Immgenuity, Inc. Enters Into a Scientific Collaboration Agreement with OHSU

Dover, Delaware, February 13, 2023 - Immgenuity, Inc., a leading biotechnology company focused on developing innovative immunotherapy for HIV to effect remission, announced today that it has entered into a scientific collaboration agreement with Oregon Health & Science University (OHSU).

Under the terms of the agreement, Immgenuity and OHSU will collaborate to advance the development of novel immunotherapies for the treatment of cancer and other diseases. The collaboration will leverage Immgenuity's expertise in developing cutting-edge technologies for the identification and characterization of immune cell populations, mechanisms of immune escape and OHSU's deep knowledge of HIV, NeuroAIDS and clinical development. OHSU's component bodies, namely the Jungers Center for Neuroscience Research and the Vollum Institute, shall provide additional guidance and expertise in advancing Immgenuity's research.

"We are excited to partner with OHSU, a renowned institution with a strong track record of innovation in the fields of HIV and NeuroAIDS," said Dr. Sateesh Apte, CEO of Immgenuity. "By combining our respective strengths and expertise, we believe we can make significant progress in the development of new immunotherapies that can address HIV persistence, NeuroAIDS and improve patient outcomes. Research on our therapeutic vaccine for HIV, IMTV014, will be greatly enhanced by our collaboration with OHSU."

The collaboration will be led by Immgenuity's Chief Scientific Officer and Marcel Curlin, M.D., Associate Professor of Medicine at OHSU. The teams will work closely together to advance the research program and identify new approaches and clinical strategies.

"We are thrilled to partner with Immgenuity on this important initiative," said Dr. Curlin. "This collaboration has the potential to accelerate the development of new immunotherapies that can make a meaningful difference in the lives of patients with HIV."

About Immgenuity, Inc.

Immgenuity, Inc. is a biotechnology company dedicated to developing innovative immunotherapy solutions to improve the lives of patients suffering from HIV. The company's lead product candidate is IMTV014, a novel immunotherapy for HIV and NeuroAIDS, which has shown to be safe in preclinical studies. Immgenuity, Inc. is headquartered in Dover, Delaware and is led by a team of experienced biotech professionals with deep expertise in infectious diseases, immunology, virology, and drug development. For more information, visit <https://immgenuity.com>

About IMTV014

Immgenuity's immunotherapy, IMTV014 is a genetically modified HIV virus which is unable to block immune signaling like the natural HIV does. By restoring immune signaling, IMTV014 plans to activate the immune system to create a strong, viable immune response against HIV and likely lead to clearing

the virus even from the sanctuary areas where the virus persists despite aggressive anti-HIV drug treatment. IMTV014 will also address various neurological and cardiovascular comorbidities caused by the virus persistence in these anatomical sanctuary areas via prolonged and elevated secretion of inflammatory cytokines. IMTV014 also has application as “salvage therapy” in the multidrug resistant population.

About OHSU

Oregon Health & Science University is a public research university located in Portland, Oregon. The university is a leader in biomedical research, with a focus on cancer research, neuroscience, and infectious diseases. OHSU is also a major center for clinical care, providing high-quality medical services to patients in the Pacific Northwest and beyond.

Contact: Media Relations: media@immgenuity.com (302) 321-5844

Forward Looking Statements:

This press release contains “forward-looking statements” within the meaning of federal securities law, including statements concerning the company’s outlook for 2023 and beyond; business strategies and their anticipated results; and similar statements concerning anticipated future events and expectations that are not historical facts. The forward-looking statements in this letter are subject to numerous risks and uncertainties, including the effects of economic conditions; supply and demand changes; competitive conditions in the industry; relationships with clients and distributors; the impact of government regulations; and the availability of capital to finance growth, which could cause actual results to differ materially from those expressed in or implied by the statements herein.